UK markets close in 5 hours 36 minutes

Eagle Pharmaceuticals, Inc. (1E6.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
3.8400+0.1400 (+3.78%)
As of 08:16AM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 49.46M
Enterprise value 101.97M
Trailing P/E 4.66
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.20
Price/book (mrq)0.20
Enterprise value/revenue 0.40
Enterprise value/EBITDA 1.82

Trading information

Stock price history

Beta (5Y monthly) 0.41
52-week change 3-85.55%
S&P500 52-week change 323.57%
52-week high 327.0000
52-week low 33.7000
50-day moving average 34.8488
200-day moving average 38.9691

Share statistics

Avg vol (3-month) 313
Avg vol (10-day) 3N/A
Shares outstanding 512.96M
Implied shares outstanding 613.69M
Float 810.39M
% held by insiders 112.02%
% held by institutions 186.58%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Jun 2023

Profitability

Profit margin 4.64%
Operating margin (ttm)15.94%

Management effectiveness

Return on assets (ttm)6.63%
Return on equity (ttm)4.88%

Income statement

Revenue (ttm)257.55M
Revenue per share (ttm)19.68
Quarterly revenue growth (yoy)-12.80%
Gross profit (ttm)N/A
EBITDA 62.33M
Net income avi to common (ttm)11.95M
Diluted EPS (ttm)0.7900
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)15.35M
Total cash per share (mrq)1.18
Total debt (mrq)72.45M
Total debt/equity (mrq)28.75%
Current ratio (mrq)2.16
Book value per share (mrq)19.25

Cash flow statement

Operating cash flow (ttm)-9.32M
Levered free cash flow (ttm)38.31M